Mesoblast Limited (ASX:MSB) Announce United States FDA Clears Phase 2 Trial For Congestive Heart Failure
Australia’s regenerative medicine company, Mesoblast Limited (ASX:MSB)(USOTC:MBLTY)(PINK:MEOBF), announced that the United States Food and Drug Administration (US FDA) had cleared an Investigational New Drug (IND) submission by its US-based sister company, Angioblast Systems Inc., to commence a Phase 2 trial of the stem cell platform technology for treating patients with congestive heart failure.
More: continued here
Filed under: Stem Cell Research on June 10th, 2008